| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries
|
El Kibbi, Lina
|
|
|
4 |
3 |
p. e160-e163
|
artikel
|
| 2 |
Battling burnout
|
The Lancet Rheumatology,
|
|
|
4 |
3 |
p. e153
|
artikel
|
| 3 |
Call for papers: Sex and gender in rheumatology
|
Van Epps, Heather
|
|
|
4 |
3 |
p. e168
|
artikel
|
| 4 |
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab
|
Strand, Vibeke
|
|
|
4 |
3 |
p. e198-e207
|
artikel
|
| 5 |
Correction to Lancet Rheumatol 2021; 3: e789–97
|
|
|
|
4 |
3 |
p. e174
|
artikel
|
| 6 |
COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1
|
Saleem, Benazir
|
|
|
4 |
3 |
p. e171-e172
|
artikel
|
| 7 |
From phenotype to pathophysiology—placing rheumatic diseases in an immunological perspective
|
van Wesemael, T J
|
|
|
4 |
3 |
p. e166-e167
|
artikel
|
| 8 |
Health-care workers recovered from natural SARS-CoV-2 infection should be exempt from mandatory vaccination edicts
|
McGonagle, Dennis G
|
|
|
4 |
3 |
p. e170
|
artikel
|
| 9 |
Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab
|
Smetanova, Jitka
|
|
|
4 |
3 |
p. e163-e166
|
artikel
|
| 10 |
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
|
Jyssum, Ingrid
|
|
|
4 |
3 |
p. e177-e187
|
artikel
|
| 11 |
Interpreting the efficacy of secukinumab on patient-reported outcomes in psoriatic arthritis
|
Gossec, Laure
|
|
|
4 |
3 |
p. e159-e160
|
artikel
|
| 12 |
Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus
|
Stamm, Tanja
|
|
|
4 |
3 |
p. e157-e159
|
artikel
|
| 13 |
Puja Mehta: taking the path untrodden
|
Thorley, Jennifer
|
|
|
4 |
3 |
p. e176
|
artikel
|
| 14 |
Research in Brief
|
Thorley, Jennifer
|
|
|
4 |
3 |
p. e175
|
artikel
|
| 15 |
Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
|
Boekel, L
|
|
|
4 |
3 |
p. e154-e155
|
artikel
|
| 16 |
Severe COVID-19 as a virus-independent immunothrombotic process
|
Cherian, Robin
|
|
|
4 |
3 |
p. e172-e173
|
artikel
|
| 17 |
Severe COVID-19 as a virus-independent immunothrombotic process – Authors' reply
|
McGonagle, Dennis
|
|
|
4 |
3 |
p. e173
|
artikel
|
| 18 |
Thank you to our peer reviewers in 2021
|
The Editors of The Lancet Rheumatology,
|
|
|
4 |
3 |
p. e168-e169
|
artikel
|
| 19 |
The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
|
Strand, Vibeke
|
|
|
4 |
3 |
p. e208-e219
|
artikel
|
| 20 |
The STAR care pathway for patients with pain at 3 months after total knee replacement: a multicentre, pragmatic, randomised, controlled trial
|
Wylde, Vikki
|
|
|
4 |
3 |
p. e188-e197
|
artikel
|
| 21 |
The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice
|
Day, Julia
|
|
|
4 |
3 |
p. e220-e228
|
artikel
|
| 22 |
Wider considerations following evaluation of the STAR care pathway for patients with painful knee replacement
|
Beard, David
|
|
|
4 |
3 |
p. e155-e157
|
artikel
|
Tijdschrift beschrijving